Peptide profile
Bremelanotide
Also known as PT-141
Melanocortin receptor agonist
Approved medicines exist
Science, with its context intact.What to knowThe evidence
The evidence
in perspective.
Vyleesi has a specific FDA-approved indication for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is not approved as a general performance enhancer.
View the supporting source- Research area
- Endocrine
- Biological target or mechanism
- Melanocortin receptor agonist
- Evidence context
- Approved medicines exist
- Availability
- Availability requires pharmacy review
From information to a conversationClinical decisions stay
Clinical decisions stay
with clinical professionals.
This profile is a research reference. Your prescriber and pharmacy assess the relevant clinical and dispensing pathway. Inclusion here is not an offer to sell this compound.
